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Epilepsy is a common chronic neurologic disorder affecting approximately 1% of the
world population. More than one-third of all epilepsy patients have incompletely controlled
seizures or debilitating medication side effects in spite of optimal medical management.
Medically refractory epilepsy is associated with excess injury and mortality, psychosocial
dysfunction, and significant cognitive impairment. Effective treatment options for these
patients can be limited. The cellular mechanisms underlying seizure activity are incom-
pletely understood, though we here describe multiple lines of evidence supporting the
likely contribution of astroglia to epilepsy, with focus on individual astrocytes and their
network functions. Of the emerging therapeutic modalities for epilepsy, one of the most
intriguing is the field of neuromodulation. Neuromodulatory treatment, which consists of
administering electrical pulses to neural tissue to modulate its activity leading to a benefi-
cial effect, may be an option for these patients. Current modalities consist of vagal nerve
stimulation, open and closed-loop stimulation, and transcranial magnetic stimulation. Due
to their unique properties, we here present astrocytes as likely important targets for the
developing field of neuromodulation in the treatment of epilepsy.
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INTRODUCTION
Epilepsy is a common chronic neurologic disorder affecting 0.5–
1% of the population with an estimated lifetime risk greater than
4% (Hauser et al., 1993; Hesdorffer et al., 2011). More than one-
third of all epilepsy patients have incompletely controlled seizures
or debilitating medication side effects in spite of optimal medical
management (Sander, 1993; Kwan and Brodie, 2000; Sillanpaa and
Schmidt, 2006). Medically refractory epilepsy is associated with
excess injury and mortality, psychosocial dysfunction, and signifi-
cant cognitive impairment (Brodie and Dichter, 1996). Treatment
options for these patients include new antiepileptic drugs (AEDs),
which may lead to seizure freedom in a small percentage of patients
(Fisher, 1993; Engel, 2012) and resective surgery which is associ-
ated with long term seizure freedom in 60–80% of patients (Engel
et al., 2003; Lee et al., 2005b; Engel, 2012). The cellular mechanisms
underlying seizure activity are incompletely understood, though
multiple lines of evidence support the contribution of astrocytic
cells, both individually and in networks. Many properties of astro-
cytes also make them important targets for the developing field of
neuromodulation in the treatment of epilepsy.
ASTROCYTES IN EPILEPSY
Historically, astroglia were thought to provide only metabolic and
physical support for neurons. They serve as the primary source
of energy for neurons (Brown et al., 2004) and serve to control
ionic homeostasis and neuronal excitability by buffering potas-
sium (Kofuji and Newman, 2004). It is now clear, however, that
astroglia are directly involved in neuronal signaling, even locally
at synapses (Barres, 1991; Bergles et al., 1997; Volterra et al.,
2002; Hatton and Parpura, 2004; Lin and Bergles, 2004; Allen and
Barres, 2005; Volterra and Meldolesi, 2005). Astroglia synthesize
and recycle glutamate (Hertz and Zielke, 2004) and respond to
synaptic release of neurotransmitters with both calcium waves
and release of gliotransmitters that can further influence synaptic
activity (Cornell-Bell et al., 1990a; Grosche et al., 1999; Schipke
and Kettenmann, 2004; Pascual et al., 2005; Perea and Araque,
2005; Zorec et al., 2012), with important implications in the
epileptic brain (Carmignoto and Haydon, 2012). Perisynaptic
astroglial processes may detect spill out of glutamate and other
substances from active synapses (Rusakov and Kullmann, 1998;
Diamond, 2005), and respond structurally by extending and mod-
ifying their processes (Cornell-Bell et al., 1990b; Hirrlinger et al.,
2004; Witcher et al., 2007, 2010). Variation in synapse strength
and the degree to which substances escape the perimeter might
determine whether astroglial processes grow toward and ensheath
parts of some synapses and avoid or retract from others (Cornell-
Bell et al., 1990b; Hatton and Parpura, 2004; Witcher et al., 2007).
Astroglia also secrete substances that are critical to the formation
and function of synapses during development (Mauch et al., 2001;
Ullian et al., 2001, 2004; Christopherson et al., 2005; Goritz et al.,
2005) and contain contact-mediated factors that influence synapse
maturation (Mazzanti and Haydon, 2003; Murai et al., 2003; Hama
et al., 2004).
Astrocytes also function as modulators of neurotransmitters. It
is commonly accepted that astrocytes play a large role in glutamate
uptake, mostly through the GLT-1 transporter (Danbolt, 2001),
also known as the excitatory amino acid transporter-2 (EAAT2)
transporter with assistance by additional uptake via the EAAT1
transporter (Shigeri et al., 2004). Astrocytes, through the regula-
tion of extracellular glutamate diffusion, also appear to modulate
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intersynaptic crosstalk (Oliet et al., 2001, 2006; Theodosis et al.,
2006) and modulate synaptic function (Piet et al., 2004). Astrocytic
transporter placement may only be contributory to these effects,
however, as glutamine synthetase plays a key role in the metab-
olism of uptaken glutamate (Magistretti, 2006). While glutamine
synthetase has been shown to be upregulated in reactive astro-
cytes (Eddleston and Mucke, 1993), it appears to be reduced in the
epileptic hippocampus (Eid et al., 2004; van der Hel et al., 2005),
indicating potential changes in the uptake potential of astrocytic
transporters. Glutamate transporters have similarly been shown
to be reduced in the epileptic hippocampus (Proper et al., 2002).
Similarly,GABA release from interneurons may be proportionately
increased by intracellular astrocytic calcium through activation
of the kainic subtype of neuronal ionotropic glutamate recep-
tors (Liu et al., 2004). Disruption of this cycle could lead to
a decrease in GABA release, and thus decreased inhibition of
neurons. GABA and glutamate imbalance is believed to poten-
tially be a key mechanism in pathologies such as epilepsy. Thus,
astroglia likely modulate function of synapses individually and
within synaptic networks.
ASTROCYTIC CHANGE IN NEUROPATHOLOGY CAN ALTER
FUNCTION OF NEURONAL NETWORKS
Multiple pathologically induced changes in astrocytic function
have been described. For example, neuronal calcium homeosta-
sis may be modulated by growth factors such as NGF, known
to be released by astrocytes in response to excitotoxic injection,
providing a means of protecting cultured neurons against exci-
totoxicity (Eddleston and Mucke, 1993). Extracellular levels of
calcium, as well as the propagation of multicellular calcium waves
may be tied intricately to mechanically induced stimulation in
astrocytes (Ostrow and Sachs, 2005). Under pathological condi-
tions, mechanical stimulation could be provided in the injured
CNS by reactive gliosis, swelling, mass effects, or tissue hyper-
trophy (Ostrow and Sachs, 2005). Astrocytic dysregulation of the
vascular system has also been implicated in the epileptic brain.
For example, altered calcium signaling by astrocytes can result in
changes in local vascular tone (Zonta et al., 2003; Gomez-Gonzalo
et al., 2011). Additionally, the upregulation or induction of multi-
ple inflammatory factors within perivascular astrocytes, including
IL-1β, complement components, and plasminogen activator in
the epileptic brain may also have dramatic effects on the vascu-
lar system leading to disruption of the blood brain barrier (as
reviewed in Aronica et al., 2012). Dysfunctional astrocytic calcium
signaling may also underlay the development of a recurrent excita-
tory loop sustaining ictal discharge (Gomez-Gonzalo et al., 2010).
Astrocytic dysfunction can also result in neuronal oxidative stress
(Takuma et al., 2004), as failed support of dopaminergic neurons
has been detected after astrocytes were experimentally deprived of
glutathione (Drukarch et al., 1997).
Pathological dysfunction has also been observed in the gap-
junctional coupling of astrocytes. Along these lines, increases have
been noted in the expression of connexin-43 in experimental
excitotoxic injuries (Haupt et al., 2007) as well as from epilep-
tic patient specimens (Naus et al., 1991). Upregulation may result
in increased intercellular signaling through calcium waves (Scemes







FIGURE 1 | Reconstructed dendrites, synapses, and associated
astroglial processes from rodent hippocampus. (A)Three-dimensional
reconstruction of a single astroglial process (blue) interdigitating among
many dendrites, four of which are reconstructed here (gold, yellow, red, and
purple). Axonal boutons are not displayed. (B) Approximately 50% of the
Axon-Spine Interface (ASI) of a mushroom spine was apposed by astroglia
(arrows). (C) Only the neck of this thin dendritic spine was apposed by
astroglia (arrows). Scale bar in (C) is for (B) and (C). Figure reproduced with
permission from John Wiley and Sons.
release (Parpura et al., 2004), and may play a role in the potassium
buffering capacity of astrocytes (Wallraff et al., 2006). Through gap
junctions, astrocytes can exert neurotrophic and neuroprotective
influences (Naus et al., 2001; Takuma et al., 2004). Conversely,
gap junction communication can be reversed in pathological con-
ditions such as hypoxia (Martinez and Saez, 2000), potentially
resulting in increased neuronal injury (Ozog et al., 2002).
It is therefore clear that astroglial cells function to support the
microenvironments of neuronal cells and to modulate neural net-
works. Given their unique structural interactions with multiple
neuronal contacts simultaneously (Figure 1; originally published
in Witcher et al., 2007; and Movie S1 in Supplementary Material),
it is evident that astrocytes can readily integrate into a functional
network. Astroglial cells may even function as separate, parallel
networks in roles not currently understood. It is highly likely
that astroglial networks have a fundamental role in disease states
addressed through neurosurgical approaches. Specifically, astro-
cytes play a vital role in the epileptic brain, the treatment algorithm
of which often ends in neurosurgical resection, transection, or dis-
connection of cellular networks. Similarly, multiple neurosurgical
entities currently depend on the modulation of cerebral net-
works through introduction and manipulation of neuromodula-
tory devices such as deep brain stimulators. These techniques have
analogous implications for astrocytes and the astroglial network.
These disease processes include dystonia, movement disorders
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such Parkinson’s disease and psychological disorders dependent on
appropriate modulation of network function such as Obsessive-
Compulsive Disorder, depression, and others. Through a better
understanding and manipulation of the astrocytic networks of the
human brain, we hypothesize that new targets and modulatory
therapies can be developed in the treatment of epilepsy.
IMPLICATIONS IN EPILEPSY
One of the most consistently reported findings associated with
seizure activity, whether a single event caused experimentally by
focal application of convulsants (Jiang et al., 1998) or by repeated
epileptic seizures in vivo (Scheibel and Scheibel, 1977), is hip-
pocampal neuronal loss, subsequent deafferentation of dendritic
partners, and loss of dendritic spines. Hippocampal alterations in
mesial temporal lobe epilepsy (MTLE) include neuronal loss in
the hippocampus, gliosis, and reorganization of subsets of neu-
rons in the hippocampus (Sommer, 1880; Spencer, 2002). Lesions
of CA1, in particular, are associated with the classically described
Ammon’s Horn sclerosis (Mathern et al., 1997; Duvernoy, 2005),
and greater loss of spines is associated with a greater degree of
pathology. Other findings consistently reported in epileptic tissue
include denuding of dendritic segments, as well as the forma-
tion of varicosities along dendritic shafts (Multani et al., 1994).
The degree of synaptic loss can vary along individual dendrites
(Scheibel and Scheibel, 1977). As reviewed by Fiala et al. (2002),
these pathologies are also consistent with other neurodegenera-
tive disorders, many of which cause deafferentation of dendrites.
This observation led to the hypothesis that deafferentation may be
the cause of dendritic spine pathology associated with disorders
including epilepsy (Swann et al., 2000; Fiala et al., 2002). Structural
evidence including the presence of giant spines, tortuous spines,
an appearance of axon-free post synaptic densities (PSD) in den-
dritic spines, and aberrant synaptic partners (Raisman and Field,
1973; Baloyannis and Kim, 1979; Chen and Hillman, 1982) could
support this hypothesis.
While recent attention has focused on changes in glial function
in neurological diseases such as epilepsy (Tian et al., 2005; Binder
and Steinhauser, 2006; Lee et al., 2006b; Matute et al., 2006), associ-
ated changes in perisynaptic astrocytic structure have been less of a
focus, though changes in the amount of synaptic astrocytic contact
would also be expected in the epileptic hippocampus. Important
findings established or implicated in this form of epilepsy include
increases in extracellular glutamate (During and Spencer, 1993),
decreases in glutamate metabolism (Malthankar-Phatak et al.,
2006), decreases in glutamate-stimulated GABA release (During
et al., 1995), increased GABA transporter expression (Lee et al.,
2006b), and increased lactate levels (Cavus et al., 2005), all of which
can be associated with astrocytic dysfunction. While multiple stud-
ies have addressed the morphological changes of reactive astro-
cytes (Krishnan et al., 1994; van Paesschen et al., 1997; Mitchell
et al., 1999; Briellmann et al., 2002) ultrastructural alterations
remain understudied. Of primary importance is evidence which
contradictorily supports both increased and decreased association
between synaptic partners and astrocytic processes.
Multiple lines of evidence would support the possibility of
increased perisynaptic astroglial apposition in the epileptic brain.
The first is that in the epileptic hippocampus, microdialysis studies
indicate that extracellular glutamate levels rise prior to and during
ictal onset, peaking at levels associated with potential neurotoxicity
(During and Spencer, 1993). Previous work has shown that astro-
cytes are responsible for the removal of extracellular glutamate,
and that astrocytic presence can be neuroprotective (Rosenberg
and Aizenman, 1989). Increased presence of perisynaptic astro-
cytic processes could therefore potentially serve as a mechanism by
which to lower glutamate concentrations to baseline levels. It has
also been shown that astrocytic processes are attracted to the neu-
rotransmitter glutamate (Cornell-Bell et al., 1990b). The source
of extracellular glutamate is likely synaptic in nature. It is there-
fore plausible that astrocytic processes would be drawn to these
remaining synapses.
Further supporting increased apposition are the findings that
astroglial contact stabilizes larger synapses (Witcher et al., 2007)
and increases the efficacy of synaptic transmission (Pfrieger and
Barres, 1997). The effects of increasing the amount of apposition
at individual synapses is currently unknown, but previous research
suggests that the amount of surround is not correlated to synapse
size (Ventura and Harris, 1999) and that any amount of synaptic
contact may be significant (Witcher et al., 2007). As synaptic loss
is a known consequence of epilepsy, astrocytic apposition could
function to stabilize remaining synapses.
Finally, previously reported increases in individual neurotrans-
mitter receptor could support increased apposition, since MTLE is
associated with an increase in glutamate receptors in the epileptic
hippocampus. Human hippocampal astrocytes, similar to neu-
rons, contain a wide variety of glutamate receptors, including
AMPA receptors (Seifert et al., 2004; Matute et al., 2006), which are
increased in CA1 in human epileptic tissue (Brines et al., 1997).
Given the established concomitant decrease in neuronal density in
epileptic hippocampi, it is plausible that this glutamate receptor
increase is in the astrocytic component of the neuropil.
In contrast to the preceding evidence, other findings support
the likelihood that perisynaptic astrocytic apposition could instead
be decreased in epilepsy. One line of evidence lies in the morpho-
logical changes which take place subsequent to neuronal deaf-
ferentation. Due to the decrease in hippocampal neuronal density
and concomitant dendritic pathologies consistently reported in
both experimental and human epilepsy (Scheibel and Scheibel,
1977; Belichenko and Dahlstrom, 1995; Drakew et al., 1996;
Thompson et al., 1996), it has been hypothesized that epilepsy
serves as a model of neuronal deafferentation (Swann et al., 2000;
Fiala et al., 2002). In the hippocampus, Schaffer collateral axons
provide excitatory input from CA3 pyramidal neurons to CA1
pyramidal neurons via apical dendrites in CA1 stratum radia-
tum. In MTLE, where neuronal loss is prominent in both the
hippocampal subfields of CA3 and CA1, loss of CA3 pyramidal
neurons results in deafferentation of CA1 pyramidal neurons. As
reported from other brain regions, astrocytic withdrawal can result
in increased signaling between postsynaptic and presynaptic part-
ners (Oliet et al., 2001), as well as increased signaling between
adjacent synapses (Piet et al., 2004). Similarly, astrocytic with-
drawal has been shown to regulate synaptic connectivity in the
arcuate nucleus (Fernandez-Galaz et al., 1997) and similar effects
have been implicated in the hippocampal dentate hilus (Luquin
et al., 1993; Klintsova et al., 1995). Therefore, decrease in astrocyte
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surround at the synapse could be a compensatory mechanism
useful for increasing axonal input to deafferented dendrites.
Modifications in the pattern of glutamate transporter expres-
sion in the sclerotic human hippocampus provide further support
for astrocytic withdrawal from synapses. As many as five types
of glutamate transporters have been described as present, and
are designated as EAAT1–5, as reviewed by Danbolt (2001). The
major glutamate transporters associated with hippocampal astro-
cytes include EAAT1 (GLAST), EAAT2 (GLT), and EAAT3 (EAAC)
while the other EAAT subtypes are typically associated only with
neurons (Danbolt, 2001). In addition to the astrocytic distribution
of EAAT2, a presynaptic neuronal distribution was also shown in a
subpopulation of excitatory hippocampal terminals, including the
CA1 (Chen et al., 2002, 2004). In the CA1 subfield, approximately
60% of astrocytic membranes contain EAAT2 transporter proteins
compared to approximately 30% of neurons (Chen et al., 2004).
EAAT2 localizes in the cellular membrane of astrocytes (Danbolt,
2001), while in neurons it appears to label in the membrane as well
as the cytoplasm (Chen et al., 2002, 2004). EAAT3 transporters, by
contrast, appear to have a cytoplasmic distribution in both astro-
cytes and neurons (Danbolt, 2001). The distribution of EAAT1,
however, is strictly astrocytic and localized almost exclusively to
cytoplasmic membranes (Danbolt, 2001).
The EAAT1 transporter concentration does not vary between
the soma and processes of astrocytes, but varies relative to neigh-
boring structures, where concentration is increased along mem-
branes apposing neuropil, and decreased in membrane apposing
cellular somata, pial surfaces, or capillary endothelium (Danbolt,
2001). The EAAT1 transporter is therefore a reliable marker of
astrocytic membrane in the neuropil, and can be particularly use-
ful in the distal processes of astrocyte where GFAP filaments do
not extend (Bushong et al., 2002, 2004). While the EAAT2 trans-
porter is associated with the majority of glutamate uptake from
the hippocampus, and a causative relationship has been shown
between its knockout and the development of lethal, spontaneous
seizures (Tanaka et al., 1997), its expression in neurons makes it
non-specific to astrocytic membranes.
In the sclerotic human hippocampus, expression of the EAAT2
transporters are significantly decreased in CA1, and EAAT1 levels
show a similar trend (Proper et al., 2002). Paradoxically, a well-
known consequence of sclerosis is the hypertrophy of astrocytes,
demonstrated repeatedly through expansion of the GFAP protein
unique to astrocytic soma and perisomatic processes. This pro-
tein, however, is absent in small, distal astrocytic processes, such
as those that appose synaptic membranes (Bushong et al., 2002).
As the EAAT1 and EAAT2 transporters are localized in all por-
tions of the astrocytic membrane regardless of distance from the
soma, they serve as indicators of the astrocytic processes distal to
the appearance of GFAP. While the decrease in EAAT2 is signifi-
cant in TLE (Proper et al., 2002), the trend toward a concomitant
decrease in astrocyte-specific EAAT1 suggests that the decrease is
likely contributed to by astrocytic changes. Decrease in these trans-
porters suggests a decrease in non-GFAP containing perisynaptic
astrocytic processes, thereby supporting a potential withdrawal of
these processes.
Using three-dimensional unbiased brick analysis, multiple
interesting findings were recently shown from the human epileptic
hippocampus (Witcher et al., 2010). Specifically, it was shown that
synaptic loss was indeed associated with the process of epilepto-
genesis, and that synaptic density decreased as gliosis increased.
It was also shown that the morphology of remaining synapses
was altered, and in the severe epileptic state, normal-appearing
neuronal spines were replaced by abnormal giant spines which
likely have unique physiological properties. Remaining synapses
did not show increased numbers of vesicles, refuting the idea that
high extracellular glutamate (During and Spencer, 1993; Cavus
et al., 2005) is likely based on decreased uptake of the neurotrans-
mitter. Synapses remaining in the epileptic hippocampus were
not restricted from intersynaptic communication (Witcher et al.,
2010). Despite these changes, however, it was clear that the apposi-
tion of perisynaptic astroglia supported larger synapses (Witcher
et al., 2007, 2010). Therefore, while the astroglia and synapses
show fundamental changes in the pathologic brain, it is clear that
positive benefits arise from the relationship.
Neurosurgical management of epilepsy is useful in patients who
are refractory to optimized medical treatment (Engel et al., 2003;
Lee et al., 2005b). Current modalities are dominated by resec-
tion or disconnection of epileptic cellular networks. Descriptions
of modern methods and their psychosocial implications occupy
a vast literature and include lesionectomies, anterior temporal
lobectomy, amygdalohippocampectomy, extratemporal resection,
and corpus callosotomy (Feindel et al., 2009; Wilson and Engel,
2010). There is also a developing role for stereotactic radio-
surgery (Quigg et al., 2012). In spite of improvements in surgical
technique, approximately 4% of patients will suffer death or per-
manent neurologic disability (ILAE, 1997). Moreover, more than
one-third of patients will not be candidates for surgical resection
(Kwan and Brodie, 2000). For patients who are not candidates
for resective surgery, there are limited options. Neuromodula-
tory treatment, which consists of administering electrical pulses
to neural tissue to modulate its activity leading to a beneficial
effect (Witcher and Ellis, 2011), can be effective for these patients.
NEUROMODULATION AND ASTROGLIAL IMPLICATIONS
The interest in neuromodulation for neurological disorders is dri-
ven by a desire to discover less invasive surgical treatments, as
well as new treatments for patients whose medical conditions
remain refractory to existing modalities (Witcher and Ellis, 2011).
Interestingly, the unique characteristics of astrocytes make them
interesting targets in the developing field of neuromodulation.
Specifically, the use of these technologies requires modulation of
large neural networks, and likely involve modulation of or through
astrocytes or astroglial networks. These mechanisms likely involve
reactive astrocytosis, network manipulation, and modulation of
the release of gliotransmitters.
Astrocytic processes are ubiquitous between cells and around
excitatory synapses throughout the CNS (Witcher et al., 2007,
2010). This proximity of astrocytic processes to synapses allows
synaptic placement of glutamate transporters at sites of glutamate
release and also the ability to limit or delimit interactions between
neighboring synapses (Witcher et al., 2007, 2010). Astrocytes have
also been shown to express metabotropic receptors for many neu-
rotransmitters, including glutamate, GABA, norepinephrine, and
acetylcholine (Tritsch and Bergles, 2007). Astrocytic responses
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to the activation of these receptors implies sensing of neuronal
function and results in oscillations or repetitive spikes in Ca2+,
which likely has influence over neuronal network function (Di
Castro et al., 2011; Takata et al., 2011). Gliotransmitters, namely
ATP, d-serine, and glutamate are release in response to neuronal
and astrocytic stimulation which also could cause neuronal net-
work effects (Santello and Volterra, 2009; Halassa and Haydon,
2010). Mechanisms eliciting neuronal responses have been stud-
ied in both culture and slice models and include stimulation of
metabotropic receptors, photolysis of caged IP3 or infused caged
Ca2+, and repetitive depolarization of the astrocyte membrane
presynaptic (Araque et al., 1998; Parri et al., 2001; Fiacco and
McCarthy, 2004; Fellin et al., 2004; Jourdain et al., 2007).
Vagal nerve stimulation (VNS) is one example of neuromodu-
lation that was developed in the 1980s, and which is now routinely
available (Ben-Menachem, 2002). VNS, as an adjunct to medical
management, may yield up to a 50% reduction in seizure fre-
quency (VNSSG, 1995) although most of these patients will not
be seizure free. Deep brain stimulation (DBS) is another example
of neuromodulation. Given the significant experience and success
of DBS for movement disorders (Krack et al., 2003) combined
with its reversibility, programmability, and low risk of morbid-
ity, there has been a resurgence of interest in using DBS devices
for treating medically refractory epilepsy. Responsive neurostim-
ulation (RNS) is a technology that detects seizure activity at a
previously defined focus and applies an electrical stimulus to the
site of seizure onset to terminate the seizure. Lastly, transcranial
magnetic stimulation (TMS) is a nearly 25-year-old technology
initially introduced as a means to non-invasively investigate cor-
ticospinal circuits. Currently, TMS is used primarily in clinical
neurophysiology. Importantly, TMS can be used to evaluate and
manipulate excitatory and inhibitory intracortical circuits with
poststimulatory effect, allowing for a developing use in epilep-
tic neuromodulation. A growing body of literature supports the
involvement of astrocytes in the realization of therapeutic goals
for each of these modalities, and will be reviewed below.
VAGAL NERVE STIMULATION
The vagal nerve has a complex anatomical arrangement which
projects to the autonomic and reticular structures and well as lim-
bic and thalamic neurons. Stimulation of the vagus-nerve and
its bilateral multisynaptic targets has become a common tech-
nology for the treatment of epilepsy. Over 50,000 patients have
been treated with the technology, and current reports indicate an
approximately 50% efficacy in seizure reduction, rivaling the effi-
cacy of antiepileptic treatment, and often decreasing dependence
on them (Labar, 2002). Efficacy has also been shown to increase
over time (Vonck et al., 1999). The low side effect profile of VNS
(Morris and Mueller, 1999) has also proven to be advantageous
for users.
The mechanism of efficacy remains unknown, though certain
structures within the brain appear to be affected by VNS. As evi-
denced by studies using positron-emission technology (PET), the
thalamus is consistently affected by VNS stimulation, and blood
flow to the cerebellum and cerebral structures is consistently
altered (Ko et al., 1996; Henry et al., 1998, 1999; Ben-Menachem,
2002). Thalamic involvement has also been supported through
SPECT (Van et al., 2000; Vonck et al., 2000) and functional MRI
(Narayanan et al., 2002; Liu et al., 2003) analysis.
Studies of VNS have been reported from multiple vertebrate
models including rodents (McLachlan, 1993), canines (Zabara,
1992), and lower primates (Lockard et al., 1990). In the rodent
penicillin/pentylenetetrazol model, interictal spike frequency was
reduced by 33% (McLachlan, 1993), the effect of which was later
found to be greatest in continuous stimulation and reduced in
a time-dependent fashion after stimulation (Takaya et al., 1996).
Later tests showed that cortical excitability in rats can be mod-
ulated through VNS (De Herdt et al., 2010). Canine strychnine
and pentylenetetrazol models show similar efficacy with lasting
reduction in motor seizures and tremors (Zabara, 1992). In the
alumina gel monkey model, seizures were eliminated in half of
test animals during stimulation periods with some persistence into
post-stimulation period (Lockard et al., 1990). Clinical trials have
indicated seizure reduction at both low and high stimulation para-
digms, with significantly greater reduction in the high stimulation
group (Handforth et al., 1998) and overall efficacy showed a mean
seizure reduction of approximately 35–45% (Morris and Mueller,
1999).
Astrocytic involvement in the regulation of the vagal nerve
nuclei supports their importance in the efficacy of VNS. McDou-
gal et al. (2011) recently demonstrated the activation of astrocytes
within the nucleus of the solitary tract (NST) when afferent stim-
ulation of the vagal nerve was applied. Using confocal, live-cell
calcium imaging of brainstem slices, they showed that afferent
activation of the vagal nerve resulted in increases in astrocytic
intracellular calcium concentrations as well as in neurons. They
then showed that the effect on astrocytes was blocked by the
AMPA receptor antagonism and was unaffected by antagonism
of NMDA and metabotropic glutamate receptors. This activation
was dependent on extracellular Ca2+ influx through AMPA recep-
tors. This Ca2+ influx was further amplified by calcium-induced
calcium release via the ryanodine receptor. Selective staining ver-
ified the presence of the AMPAR subunit GluR1 on astrocytes.
Taken together, they concluded that NST astrocytes may be active
participants in the regulation of vagal activity (McDougal et al.,
2011). This supports previous work which concluded that neurons
in the NST are regulated via astrocytic glutamate signaling under
pathologic and potentially physiologic conditions (Hermann et al.,
2009).
DIRECT NEURAL STIMULATION
Neuromodulation through the direct implantation of chronic
stimulating electrodes has become a standard of treatment in
many neurological disorders. DBS lead implantation within the
anterior nucleus of the thalamus (ANT), as well as other central
nervous system (CNS) targets – including the caudate nucleus,
centromedian nucleus of the thalamus, cerebellum, hippocampus,
and subthalamic nucleus – results in seizure reduction in selected
patients (Shandra and Godlevsky, 1990; Vercueil et al., 1998; Bra-
gin et al., 2002; Lee et al., 2006a). In these studies, stimulation
was delivered in an open-loop fashion, that is, in a pre-defined
manner, independent of the momentary physiological activity of
the brain. The exact mechanism of action of DBS in reducing
seizure activity is, however, unknown. It is known that stereotactic
Frontiers in Computational Neuroscience www.frontiersin.org August 2012 | Volume 6 | Article 61 | 5
Witcher and Ellis Astrocytes in neuromodulation
lesions of the ANT in humans can result in reduced seizure fre-
quency (Mullan et al., 1967). DBS may interfere with synchronized
oscillations by neurotransmitter release (Lee et al., 2005a). Other
evidence suggests that the most likely mechanism may involve
stimulation-induced modulation of pathologic neural networks
(McIntyre et al., 2004). High frequency DBS appears to reproduce
the clinical effect of ablative procedures (Benabid et al., 1987).
Moreover, at high frequencies, DBS may abolish cortical epilep-
tiform activity (Lado et al., 2003). A microthalamotomy effect
has been postulated based on the observation that some patients
obtain reduction in seizure frequency prior to activation of the
pulse generator (Andrade et al., 2006; Lim et al., 2007).
Although the precise mechanism by which DBS reduces seizure
activity is unclear, inhibition of neurons immediately adjacent to
the area of applied current is likely involved. A “reversible func-
tional lesion” may be generated in structures integral to initiating
or sustaining epileptic activity (Boon et al., 2007). The applied cur-
rent may inhibit neurons with a pathologically lowered threshold
of activation. Alternatively, DBS may act on neuronal network pro-
jections to nearby or remote CNS structures originating from the
area of stimulation. This might take place through either activation
of inhibitory projections or through the inhibition of excitatory
projections.
As reviewed recently by Vedam-Mai et al. (2012), high fre-
quency stimulation shows effect on astrocytic activity which has
important implications in the role of astroglia in this modality.
Astrocytes can be directly depolarized by stimulation (Kang et al.,
1998) and have the potential to modulate local and distant neural
networks using clinically relevant stimulation paradigms via the
release of gliotransmitters including ATP and glutamate (Bekar
et al., 2008; Tawfik et al., 2010).
Another important mechanism implicating astrocytes in clin-
ical efficacy is reactive astrocytosis. Reactive astrocytosis is a well
described phenomena of astrocytes at stimulator implant sites, and
is defined as astroglial hypertrophy and upregulation of GFAP and
other astrocytic proteins (Pekny and Nilsson, 2005). This finding
was described initially in cats (Stock et al., 1979) and has since
been described in multiple species including rats (Kraev et al.,
2009), non-human primates (Griffith and Humphrey, 2006), and
humans (Moss et al., 2004; Sun et al., 2008a; DiLorenzo et al., 2010;
Vedam-Mai et al., 2011). In these series, reactive elements includ-
ing multinucleated giant cells and macrophages were common
findings. In human studies, common elements included thin glial
rims surrounding the electrode tract; lymphocytes and mono-
cytes have also been described near the electrode (Moss et al.,
2004; DiLorenzo et al., 2010). The volume of the glial surround,
which could greatly impact electrode function, is, however, not
known (Moss et al., 2004). Investigation in rats, however, indicates
regional variability in astroglial reactivity to implanted electrodes
(Hirshler et al., 2010).
The effects on network activity by reactive astrocytosis then
becomes an important focus of their overall effect. Reactive astro-
cytes display marked functional changes which could include
direct neurotrophic effects though modified energetics or neu-
rotrophic factor release, enhanced glutamate uptake, reorganiza-
tion of metabolic pathways, and modulation of synaptic transmis-
sion (Liberto et al., 2004; Sofroniew, 2005; Escartin and Bonvento,
2008). Recently, a model using selective virus-induced reactive
astrocytosis in rat hippocampal area CA1 demonstrated that astro-
cytosis resulted in specific deficits in inhibitory synaptic transmis-
sion, and caused disruptions in functional regulation of circuits
resulting in enhanced excitability of the local network (Ortinski
et al., 2010). Specifically, a reduction was found in elicited mono-
synaptic inhibitory responses, which led to a reduction in basal
inhibitory neurotransmission without affecting intrinsic neuronal
properties. This resulted from an alteration in the astrocytic glu-
tamate/glutamine cycle which resulted in reduced synaptic GABA
availability (Ortinski et al., 2010). Thus, a growing body of evi-
dence supports that reactive astrocytosis at the electrode site could
readily alter network effects of targeted neural circuits.
In contrast to open-loop stimulation, contingent or closed-
loop stimulation is designed to suppress epileptiform activ-
ity by stimulating a defined epileptogenic target directly in
response to detection of abnormal EEG activity. This form of
closed-loop, responsive neural stimulation (RNS), has prelim-
inarily been shown safe and efficacious (Sun et al., 2008b),
and is currently being evaluated in a randomized trial to assess
safety and efficacy in epileptic patients. While its experimen-
tal and clinical trial background are beyond the scope of this
review, its’ similarities to DBS, notably contacting electrodes,
pulse delivery, and network neuromodulatory effects imply a
likelihood of astrocytic involvement analogous to open-loop
stimulation.
TRANSCRANIAL MAGNETIC STIMULATION
Transcranial magnetic stimulation of cortical tissues was initially
reported by Barker et al. (1985) and quickly found acceptance
as a research vehicle for neurophysiologists. TMS was initially
applied to the study of the motor system (Barker et al., 1985)
and has since expanded to include investigations in psychiatric
conditions (Pascual-Leone et al., 1996), and migraine headache
(Lipton and Pearlman, 2010). Importantly, it has also become a
viable option for the treatment of drug resistant epilepsy. TMS
exerts its effects through repetitive non-invasive stimulation in
which a pulsed magnetic field creates current flow in the brain
which can temporarily excite or inhibit target areas (Hallett,
2000).
The basis of TMS as a therapeutic neuromodulatory is derived
from the lasting effects from the application of a train of tran-
scranial stimuli. Theoretically, the lasting effects of TMS can be
used to modulate activity in focal areas of cortex (Fregni and
Pascual-Leone, 2007). The induced effect depends on the nature
of the stimulation; that is, the frequency, the timing, the focus,
and the intensity of the repetitive stimulation (Kimiskidis, 2010).
While some paradigms have been studied using animal models,
the numbers of basic studies particular to epilepsy are somewhat
limited.
Early study within the mouse hippocampal-entorhinal cortex
slice model indicated that repetitive direct (i.e., non-transcranial)
stimulation at 1 Hz can depress the generation of ictal activ-
ity in a 4-aminopyridine model (Barbarosie and Avoli, 1997),
in a frequency-dependent manner (D’Arcangelo et al., 2005).
This frequency dependence has been replicated in TMS. Low-
frequency TMS stimulation shows the tendency to lower seizure
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activity (Akamatsu et al., 2001; Godlevsky et al., 2006; Roten-
berg et al., 2008). High frequency stimulation has been shown
to potentially have both protective and inductive effects depen-
dent on the chronicity of treatment and potentially other, unex-
plored, factors (Jennum and Klitgaard, 1996; Ebert and Ziemann,
1999).
Similar results have been identified in human studies. High fre-
quency TMS has been shown to enhance cortical excitability at
high intensities (Berardelli et al., 1998), while low-frequency TMS
has been shown to reduce cortical excitability (Cincotta et al.,2003)
as well as decreased strength of neuronal signaling (Muellbacher
et al., 2000). As detailed by Kimiskidis (2010), the clinical effects
are theoretically similar to long term potentiation (LTP) and long
term depression (LTD) elicited by high- and low-frequency elec-
trical stimulation, respectively. It is therefore possible that TMS
at lower frequencies may exert its effect through the initiation of
LTD, while at higher frequencies, the proconvulsant effect may be
initiated through the induction of an LTP-type effect (Ziemann,
2005).
Direct evidence for astrocytic involvement in the neuromod-
ulatory therapy is limited. Early work in a murine model found
that high frequency TMS had a dramatic effect in the upregulation
of astroglial gene expression (Fujiki and Steward, 1997) Following
multiple high frequency trains (25 Hz), GFAP mRNA levels were
significantly increased in the hippocampal dentate gyrus to lev-
els similar to that following electroconvulsive seizures, indicating
induction of an astrocytic reactive response (Fujiki and Stew-
ard, 1997). Indirectly, the analogous effects to LTD and LTP have
important implications for astrocyte involvement, as the impor-
tant contributions of astrocytes and gliotransmitters to synaptic
plasticity have been described in multiple neuronal circuits (Yang
et al., 2003; Witcher et al., 2007; Henneberger et al., 2010; Ben
Menachem-Zidon et al., 2011; Bonansco et al., 2011; Navarrete
et al., 2012).
CONCLUSIONS AND FUTURE DIRECTIONS
In spite of optimal medical management, many patients with
epilepsy remain medically refractory and suffer from debilitating
seizures. Some of these patients may benefit from neuromodula-
tory treatment. As the evidence above indicates, it is very likely
that modulation of astroglial function is important to the efficacy
of neuromodulation. Additional studies are needed to identify
the appropriate patient populations for neuromodulation, opti-
mal targets, optimal stimulation modalities, and paradigms. It is
also critical that the cellular and network mechanisms underlying
the effects of these treatments must be better elucidated. Fur-
ther studies are needed to determine the contribution of neural
and glial components of the nervous system, and future modali-
ties must be developed which optimize both. Understanding these
relationships may enable future technologies, perhaps even nan-
otechnologies, to flourish in the developing field of therapeutic
neuromodulation.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at
http://www.frontiersin.org/Computational_Neuroscience/
10.3389/fncom.2012.00061/abstract
Movie S1 | Reconstructed dendrites, synapses, and associated astroglial
processes from rodent hippocampus. Note the spatial relationship of a single
astrocytic process (blue) interdigitating among multiple unique dendrites (gold,
yellow, red, and purple). Axonal boutons are not displayed. These spatial
relationships likely allow for the interactions of astrocytes with neurons, the
regulation of neuronal communication, and form the basis of the
astroglial-neuronal network. Figure acknowledgment to Cosmocyte, Inc.
(Savage, MD, USA) for production in rendering and display.
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